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Recent progress in melanoma drug devel-opment highlights the critical impact that translational research plays in advanc-
ing patient care. Prior to 2011, dacarbazine, 
IL-2, and IFNα-2b were the only US Food and 
Drug Administration (FDA)-approved treatment 
options for metastatic melanoma. These early 
therapies resulted in poor and inconsistent over-
all response rates (~10–15%; Eggermont and 
Kirkwood, 2004). A renaissance in melanoma 
therapeutics occurred with the recognition that 
molecular aberrations in the  mitogen-activated 
protein kinase (MAPK) pathway (Figure 1) 
were present in a majority fraction of melano-
mas (Davies et al., 2002). These investigations 
resulted in the vigorous pursuit of small-mol-
ecule kinase inhibitors and the eventual FDA 
approval of three novel MAPK pathway inhibi-
tors for the treatment of advanced melanoma 
(Figure 1). Although key insights into immune 
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Figure 1.   Molecular targeting of the mitogen-activated protein kinase (MaPK), Pi3K, and CdK4 pathways and the associated 
mutation rates of potential molecular targets in advanced melanoma (Hodis et al., 2012). Activation of a receptor tyrosine 
kinase such as c-KIT results in the propagation of signal via the MAPK pathway leading to activation of RAS, RAF, MEK, and 
ERK. This ultimately results in gene expression and promotes cellular proliferation and survival. Mutated BRAF bypasses this 
ordered pathway and stimulates constitutive signaling, making it a prime target for vemurafenib and dabrafenib. Trametinib 
targets the downstream effector molecule MEK. Dysregulation of the PI3K pathway promotes melanoma progression. Small-
molecule inhibitors of the PI3K pathway are being clinically tested in combination with MAPK pathway inhibition. Similarly, 
CDK4 is an attractive candidate molecule to target in melanoma and is the focus of multiple clinical trials. Red, activated; 
gray, inactivated; green, normal function. Drugs (shown in boxes) that have been approved (boldface) or are in trial (italics) are 
indicated. Please note that trials and drug approvals are subject to change.
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checkpoint blockade have generated a similar number of 
recent immunotherapeutic breakthroughs (Brahmer et al., 
2012; Hamid et al., 2013; Hodi et al., 2010), this Editorial 
focuses on the development of molecular targeted therapies.
Melanoma arises from the activation, or inactivation, of 
genes that regulate critical cellular functions including prolif-
eration, cell-cycle regulation, survival, angiogenesis, and cell 
migration. Efforts to systematically codify these changes have 
uncovered molecularly discrete subsets of melanoma (Curtin 
et al., 2005). For instance, melanomas arising in the context 
of non–chronic sun damaged skin are associated with BRAF 
and NRAS mutations, whereas lesions that arise from muco-
sal and acral surfaces are linked to KIT alterations (Curtin et 
al., 2005). Moreover, some melanomas that lack NRAS or 
BRAF mutations harbor deleterious lesions in NF1 or ampli-
fications of CCND1 and CDK4 (Lin et al., 2008), which are 
downstream mediators of cell-cycle progression in the MAPK 
pathway (Figure 1). These data suggest that inasmuch as mela-
nomas should be classified histologically, molecular subtyping 
may provide a more pragmatic approach as specific therapies 
targeting receptor tyrosine kinases, downstream kinases, and 
other signaling molecules become available. Table 1 highlights 
key clinical trials that have expanded the treatment landscape 
of melanoma with targeted therapies.
BraF inhibition
The rationale for targeting BRAF is evident because the Val-
600-Glu mutation in the BRAF kinase domain is the single 
most common mutation in cutaneous melanoma (Davies 
et al., 2002). This substitution constitutively activates BRAF 
and its attendant downstream MAPK pathway effectors such 
as MEK (Figure 1). Although 50% of melanomas harbor the 
BRAF V600E mutation, nearly 80% of benign nevi also con-
tain the identical mutation (Pollock et al., 2003). Thus, it is an 
early genetic lesion that is neither necessary nor sufficient to 
fully induce melanoma. Preclinical work demonstrated that 
BRAF knockdown reduced tumor formation in murine xeno-
graft models, and selective small-molecule inhibitors of RAF 
suppressed BRAF-mutant melanoma cell lines (Hoeflich et al., 
2006; Joseph et al., 2010). These translational studies show 
that BRAF is a well-validated target and set the stage for the 
development of BRAF inhibitors for clinical use.
Early studies targeting RAF employed sorafenib, a multi-
kinase inhibitor that has activity against BRAF and CRAF, but 
resulted in little to no clinical activity as monotherapy (Eisen 
et al., 2006; Ott et al., 2010). Selective BRAF inhibitors (i.e., 
those agents that specifically target mutant BRAF over wild-
type BRAF), however, demonstrated impressive results in 
melanoma. The small-molecule inhibitors vemurafenib and 
dabrafenib selectively bind the active conformation of BRAF 
and inhibit signal transduction between BRAF and MEK. A 
phase III trial, BRIM-3, of vemurafenib versus dacarbazine as 
first-line therapy for BRAF V600E–mutated metastatic melano-
ma demonstrated improved median progression-free survival 
(PFS; 5.3 vs. 1.6 months) and better overall survival (OS; 84% 
vs. 64%) at 6 months in the vemurafenib versus dacarbazine 
groups, respectively (Chapman et al., 2011). The most com-
monly detected toxicities of vemurafenib included cutaneous 
eruptions, arthralgias, photosensitivity reactions, and cutane-
ous squamous-cell carcinomas that were observed in 26% of 
patients. These results led to the FDA approval of vemurafenib 
(Zelboraf) in August 2011 for the treatment of unresectable 
BRAF V600E mutant melanoma.
Another phase III trial, BREAK-3, compared dabrafenib 
to dacarbazine in the treatment of patients with unresect-
able, metastatic, BRAF V600E mutation–positive melanoma. 
BREAK-3 demonstrated similarly impressive results as  BRIM-3. 
Patients in the dabrafenib arm had improved median PFS 
when compared to those in the dacarbazine arm, 5.1 versus 
2.7 months, respectively, with a hazard ratio (HR) for progres-
sion of 0.30 (95% confidence interval (95% CI) 0.18–0.51; P < 
0.0001) (Hauschild et al., 2012). However, one important dis-
table 1.  Key clinical trials in targeted melanoma therapy
trial Name experimental agent Control agent 
tumor response 
(experimental; 
95% Ci vs. 
control; 95% Ci)
PFS 
(experimental vs. control)
oS 
(experimental vs. control)
BRIM-3 Vemurafenib (N = 337)
Dacarbazine
(N = 338)
48%; 42–55
vs. 5%; 3–9
5.3 vs. 1.6 months (HR 0.26;
95% CI 0.20–0.33; P < 0.001)
84% vs. 64% (HR 0.37;
95% CI 0.26–0.55; P < 0.001)
BREAK-3 Dabrafenib(N = 187)
Dacarbazine 
(N = 63)
50%; 42.4–57.1
vs. 6%; 1.8–15.5
5.1 vs. 2.7 months (HR 0.30; 
95% CI 0.18–0.51; P < 0.0001)
Not statistically significant
(HR 0.76; 95% CI 0.48–1.21)
METRIC Trametinib(N = 214)
Dacarbazine
or paclitaxel 
(N = 108)
22%; 17–28
vs. 8%; 4–15
4.8 vs. 1.5 months (HR 0.45;
95% CI 0.33–0.63; P < 0.001)
81% vs. 67%  (HR 0.54;
95% CI 0.32–0.92; P = 0.01)
COMBI-d
Dabrafenib
+ trametinib
(N = 211)
Dabrafenib 
(N = 212)
67%; 60–73
vs. 51%; 45–58
9.3 vs. 8.8 months (HR 0.75;
95% CI 0.57–0.99; P = 0.03)
93% vs. 85% (HR 0.63,
95% CI 0.42–0.94; P = 0.023)
coBRIM
Vemurafenib
+ cobimetinib
(N = 247)
Vemurafenib 
(N = 248)
68%; 61–73
vs. 45%; 38–51
9.9 vs. 6.2 months (HR 0.51;
95% CI 0.39–0.68; P < 0.001)
81% vs. 73% (HR 0.65;
95% CI 0.42–1.00; P = 0.046)
COMBI-v
Dabrafenib + 
trametinib
(N = 352)
Vemurafenib 
(N = 352)
64%; 59–69
vs. 51%; 46–57
11.4 vs. 7.3 months (HR 0.56;
95% CI 0.46–0.69; P < 0.001)
72% vs. 65% (HR 0.69;
 95% CI 0.53–0.89; P = 0.005)
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tinction between the two trials is that the primary endpoint for 
BREAK-3 was PFS, whereas the co-primary endpoint for BRIM-
3 was PFS and OS. Dabrafenib also demonstrated remarkable 
efficacy in the treatment of intracranial metastases (Long et al., 
2012). Although vemurafenib and dabrafenib appear to have 
similar efficacy with respect to overall response rates, patients 
in the vemurafenib trials had higher rates of cutaneous squa-
mous-cell carcinomas, 18–25%, when compared to those in 
the dabrafenib trials, 6–11% (Chapman et al., 2011; Hauschild 
et al., 2012). BREAK-3 led to the FDA approval of dabrafenib 
(Tafinlar) in May 2013 for the treatment of unresectable mela-
noma harboring BRAF V600E.
MeK inhibition
Solit et al. (2006) reported early preclinical results that mela-
noma sensitivity to MEK inhibition was also correlated with 
the presence of the BRAF V600E mutation. Thus, pharmaco-
logic attenuation of MEK signaling represents another pos-
sible approach for BRAF-mutated tumors. Exome sequencing 
of metastatic melanoma specimens identified somatic muta-
tions in MEK1 and MEK2 as potential clinically significant 
aberrations, characterizing MEK1 and MEK2 mutations in 8% 
of melanomas (Nikolaev et al., 2012). Moreover, pharmaco-
logical MEK blockade completely abrogated tumor growth in 
BRAF mutant xenografts (Solit et al., 2006). These data pro-
vided the rationale for a phase III trial, METRIC, which com-
pared trametinib, a small-molecule selective MEK1/2 inhibitor, 
to chemotherapy (dacarbazine or paclitaxel) in the treatment 
of patients with BRAF V600E/K mutant–positive metastatic 
melanoma. Compared with patients receiving chemothera-
py, patients treated with trametinib demonstrated significant 
improvement in median PFS (1.5 vs. 4.8 months; HR 0.45; 
95% CI 0.33–0.63; P < 0.001) and 6-month OS (67% vs. 81%; 
HR 0.54; 95% CI 0.32–0.92; P = 0.01), despite being permit-
ted to cross over to trametinib. Although cutaneous eruptions 
were observed as an adverse effect in 87% of patients, tra-
metinib treatment was minimally associated with the devel-
opment of cutaneous squamous-cell carcinomas. Other toxic 
effects such as diarrhea and peripheral edema occurred in 
35% and 27% of patients, respectively (Flaherty et al., 2012b). 
Trametinib (Mekinist) gained FDA approval in May 2013 for 
the first-line treatment of patients with unresectable BRAF 
V600E/K mutant–positive melanoma. 
Combination BraF and MeK inhibition
Despite the impressive levels of tumor shrinkage observed in 
BRAF mutant melanoma patients treated with small-molecule 
BRAF inhibitors, responses are typically short lived, with a PFS 
of approximately 7 months (Chapman et al., 2011; Hauschild 
et al., 2012). Importantly, molecular studies characterized a 
number of potential mechanisms of resistance and demon-
strated that combined BRAF and MEK inhibition effectively 
abrogated resistance mediated by MEK1 mutations, BRAF 
truncation, and acquired NRAS mutations (Paraiso et al., 2010; 
Poulikakos et al., 2011; Wagle et al., 2011). To “oversuppress” 
MAPK signaling, a phase I/II trial demonstrated that combi-
nation dabrafenib and trametinib at full monotherapy doses 
improved response rate (76% vs. 54%, P = 0.03) and PFS (10.5 
vs. 5.6 months; HR 0.39; 95% CI 0.25–0.52; P < 0.001) when 
compared to dabrafenib alone, respectively (Flaherty et al., 
2012a). Based on these results, both dabrafenib and trametinib 
received accelerated FDA approval in January 2014 for use 
in the treatment of patients with metastatic melanoma with a 
BRAF V600E/K mutation. 
Three recent phase III trials corroborated these early results. 
The combination of vemurafenib and the MEK inhibitor cobi-
metinib improved PFS (9.9 vs. 6.2 months; HR 0.51; 95% 
CI 0.39–0.68; P < 0.001) and OS (68% vs. 45%; P < 0.001) 
when compared to vemurafenib alone (Larkin et al., 2014). In 
another expanded study, the combination of dabrafenib and 
trametinib improved PFS (9.3 vs. 8.8 months, HR 0.75; 95% CI 
0.57–0.99; P = 0.03) and OS (67% vs. 51%, P = 0.002) when 
compared to dabrafenib alone (Long et al., 2014). The much 
anticipated trial of the combination of dabrafenib and tra-
metinib demonstrated improved PFS (11.4 vs. 7.3 months, HR 
0.56, 95% CI 0.46–0.69; P < 0.001) and OS (72% vs. 65%, 
HR 0.69; 95% CI 0.53–0.89, P = 0.005) when compared to 
vemurafenib as monotherapy (Robert et al., 2015). Consistent 
with earlier studies, combination treatment led to lower rates 
of cutaneous squamous-cell carcinoma formation compared 
to BRAF monotherapy. Thus, at this juncture, dual BRAF and 
MEK inhibition is quickly emerging as a standard of care for 
BRAF V600E–mutated melanomas.
looking forward
Indeed, molecular targeted therapy has proven successful in 
the treatment of melanoma. Future directions include opti-
mizing the currently available drugs for maximal clinical ben-
efit and also the identification of novel therapeutic targets in 
melanoma. The previous discussion highlights the significant 
clinical benefit of selective BRAF inhibitors and the even-
tual relapse that occurs in patients treated with this modality. 
Combination therapy targeting BRAF and MEK is one poten-
tial avenue to abrogate this resistance that has been explored 
clinically. Work in human melanoma xenograft models sug-
gests another approach to delay BRAF inhibitor resistance. 
These studies demonstrate that vemurafenib-resistant mela-
noma cells maintain dependency on BRAF V600E signaling 
via BRAF V600E overexpression. Intriguingly, the vemurafenib-
resistant tumors in this model demonstrate dependence on 
vemurafenib for continued proliferation, such that cessation of 
the drug leads to tumor regression (Das Thakur et al., 2013). 
This suggests that a pulsed dosing strategy may forestall even-
tual vemurafenib-resistant tumors. As novel targeted thera-
pies for melanoma emerge, one key clinical challenge will be 
developing optimal therapeutic regimens or combinations of 
therapies that will provide the most durable clinical response.
Inasmuch as the ideal treatment regimens of the exist-
ing melanoma drugs are being investigated, therapies target-
ing novel melanoma targets are in development. Given the 
genetic diversity of melanoma cells, there exist other attractive 
 therapeutic targets including PI3K, CDK4, ERK, NF1, PPP6C, 
BCL-2, HSP90, mTOR, PDGF, Notch, MITF, and RAC1. 
Preclinical studies have begun to lay a foundation for further 
efforts to confirm clinical relevance.
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table 2.  Combined melanoma targeted therapies in progress (trials subject to change)
Clinical trial number description 
NCT01512251 BKM120 (PI3K inhibitor) + vemurafenib in BRAF V600E/K advanced melanoma
NCT01616199 PX866 (PI3K inhibitor) + vemurafenib in advanced melanoma
NCT01363232 Safety and pharmacodynamics of BKM120 (PI3K inhibitor) + MEK162 (MEK1/2 inhibitor) in advanced solid tumors
NCT01673737 Phase I/Ib trial of SAR260301 (PI3K inhibitor) ± vemurafenib in advanced cancers
NCT01820364 LGX818 (RAF inhibitor) + MEK162, BKM120, LEE011, BGJ398, or INC280 in advanced BRAF melanoma
NCT02065063 Safety, anticancer activity, and pharmacodynamics of trametinib + palbociclib (CDK4/6 inhibitor) in solid tumors
NCT01777776 Safety and efficacy of LEE011 (CDK4/6 inhibitor) + LGX818 (RAF inhibitor) in BRAF melanoma
NCT01826448 Phase1b trial of PLX3397 (Kit inhibitor) + vemurafenib in BRAF melanoma
NCT01928940 Japanese phase I/II trial of GSK2118436 (dabrafenib) + GSK1120212 (trametinib) in BRAF solid tumors and cutaneous melanoma 
NCT01433991 E7050 (cMET + VEGF inhibitor) + E7080 (VEGF inhibitor) in glioblastoma or advanced melanoma
NCT01909453 LGX818 (RAF inhibitor) ± MEK162 (MEK1/2 inhibitor) vs. vemurafenib in BRAF melanoma
NCT01701037 Dabrafenib ± trametinib before surgery in advanced melanoma that can be removed surgically
NCT01562899 MEK162 (MEK1/2 inhibitor) + AMG479 (IGFR-1 mAb) in solid tumors
NCT01519427 Selumetinib (MEK inhibitor) + MK2206 (AKT inhibitor) in advanced melanoma that failed vemurafenib or dabrafenib
NCT01271803 Vemurafenib + GDC0973 (MEK inhibitor) in BRAF advanced melanoma
NCT01380818 MEK inhibitor + PI3K/mTOR inhibitor in advanced solid tumors
NCT01781572 Phase Ib/II trial of LEE011 (CDK4/6 inhibitor) + MEK162 (MEK1/2 inhibitor) in NRAS melanoma
PteN/Pi3K
Molecular aberrations in the PI3K pathway play an important 
role in the pathogenesis of melanoma (Figure 1). The tumor 
suppressor PTEN negatively regulates PI3K signaling and has 
emerged as the dominant genetic target in the PI3K path-
way for melanoma therapies. PTEN mutations were found in 
40% of melanoma cell lines and 10% of primary melanomas 
(Guldberg et al., 1997; Tsao et al., 1998b). Moreover, forced 
expression of PTEN in PTEN-deficient melanoma tumor cells 
abrogates activation of the downstream PI3K effector molecule 
AKT and cell growth (Robertson, 2005). Mouse models have 
suggested that PTEN dysregulation acts in concert with BRAF 
V600E to promote melanoma tumorigenesis and that targeting 
both MEK and the PI3K pathway in these mice inhibits tumor 
growth (Dankort et al., 2009). These data strongly implicate 
PTEN and the PI3K pathway in the development of melano-
ma. Clinical trials targeting the PI3K pathway in combination 
with inhibiting the MAPK pathway in melanoma are currently 
underway (Table 2).
CdK4/6
Inappropriate CDK4/6 activity can result from rare activat-
ing mutations of CDK4 (Tsao et al., 1998a; Zuo et al., 1996) 
or, more commonly, loss of p16 (Figure 1). Knock-in mice 
expressing CDK4 mutations display enhanced melanoma in 
response to carcinogen exposure (Sotillo et al., 2001). Thus, 
small-molecule inhibitors targeting CDK4/6 may also be an 
effective strategy to target the cell cycle, and several agents are 
currently in clinical trials (Table 2).
The development of novel targeted therapeutic interven-
tions in the treatment of advanced melanoma demonstrates 
the importance of translational studies. Characterization of 
the molecular aberrations present in different subsets of mela-
noma cells has driven the development of therapies targeted 
specifically at mutations proven to contribute to melanoma-
genesis. Preclinical and clinical efforts have led to the recent 
approval of a number of therapeutic agents that have improved 
the PFS and OS of advanced melanoma patients. Despite these 
successes, there remains much work to be done to character-
ize and exploit other molecular targets, to overcome resistance 
and adverse effects associated with the recently approved 
agents, and to evaluate how best to combine these new inter-
ventions to maximal benefit. The bench-to-bedside model pro-
vides an effective and efficient means to achieve these goals.
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